

SOCIETY FOR REPRODUCTIVE ENDOCRINOLOGY & INFERTILITY
Classic References For Residents and Resident Educators

Abnormal Uterine Bleeding

1. Nilson L, Rybo G. Treatment of Menorrhagia. *Am J Obstet Gynecol*. 1971; 84:763-768.
2. Van Eijkeren, Christiaens GC, Geuze HJ, Haspels AA, Sixma JJ. Effects of mefenamic acid on menstrual hemostasis menorrhagia. *Am J Obstet Gynecol*. 1992; May 166(5):1419-28.
3. Bergquist A, Rybo G. Treatment of Menorrhagia with Intrauterine Release of Progesterone. *Br. J Obstet Gynaecol* 1983; March 90(3): 255-8.
4. Vancaillie G. Electocoagulation of the Endometrium with the Ball-end resectoscope. *Obstet Gynecol* 1989; Sept 74 (3 Pt 1): 425-7.
5. Fernandez H, Capella S, Audibert F. Uterine Thermal Balloon Therapy under Local Anaesthesia for the Treatment of Menorrhagia, A pilot study. *Human Reproduction* 1997 Nov 12(11): 2511-4.

Amenorrhea

1. Poretsky L, Garber J, Kleefield J, Primary amenorrhea and pseudoprolactinoma in a patient hypothyroidism. *Am J Med* 1986; 81:180.
2. Daneshdoost L, Gennarelli TA, Bashey HM, et al. Recognition of gonadotroph adenomas in women. *New Engl J Med* 1991; 324: 589.
3. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. *Fertil Steril* 1990; 53: 804.
4. Manuel M, Katayama KP, Jones Jr, HW. The age of occurrence of gonadal tumors in intersex patients with a Y chromosome. *Am J Obstet Gynecol* 1976; 124:293.
5. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. *J Clin Endocrinol Metab* 1989; 63: 412-18.
6. Burrow GN, Wortzman G, Newcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. *New Engl J Med* 1981; 304: 156.
7. Griffin JE, Edwards C, Ladden JD, Harrod MJ, Wilson JD. Congenital absence of the vagina. *Ann Intern Med* 1976; 85: 224.
8. Frank RT. Formation of artificial vagina without operation. *Am J Obstet Gynecol* 1938; 35: 1053.
9. Morris JM, Mahesh BV. The syndrome of testicular feminization in male pseudohermaphrodites. *Am J Obstet Gynecol* 1953; 65: 1192-11.
10. Kleinberg DL, Noel CL, Frantz AG. Galactorrhea; a study of 235 cases including 48 with pituitary tumors. *New Engl J Med* 1977; 296: 589-00.

11. Molitch ME. Pregnancy and the hyperprolactinemic woman. *New Engl J Med* 1985; 312: 1362.
12. Sheehan HL, Murdoch R. Postpartum necrosis of the anterior pituitary: pathological and clinical aspects. *J Obstet Gynaecol Br Emp* 1938; 45: 456-88.
13. Hivonen E. Etiology, clinical features and prognosis in secondary amenorrhea. *Int J Fertil* 1977; 22:69.
14. Warren MP, Vande Wiele RL, Clinical and metabolic features of anorexia nervosa. *Am J Obstet Gynecol* 1973; 117:435.
15. Loucks AB, Mortola JF, Girton L, Yen SSC. Alterations in the hypothalamic-pituitary-ovarian and the hypothalamic-pituitary-adrenal axes in athletic women. *J Clin Endocrinol Metab* 1989; 68:402.
16. Warren MP, Brooks-Gunn J, Hamilton LH, Warren LF, Hamilton WG. Scoliosis and fractures in young ballet dancers. *New Engl J Med* 1986; 314; 1348.
17. Carr BR. Current Evaluation and Treatment of Amenorrhea. *The American Fertility Society: Guidelines for Practice* 1994; Pgs 1-11.
18. Speroff L. Amenorrhea. *Clinical Gynecologic Endocrinology and Infertility*. 1994; Pgs 401-457.
19. Simpson JL. Genetic forms of gonadal dysgenesis. *Seminars in Reproductive Endocrinology*. 1983; Vol 1: 93.
20. Stein IF. Amenorrhea associated with bilateral polycystic ovaries. *American Journal of Obstetrics and Gynecology*. 1935; pgs 181-191.
21. Reindollar RH, Novak M, Tho SP, McDonough PG. Adult-onset amenorrhea: a study of 262 patients. *Am J Obstet Gynecol*. 1986; 155: 531-43.

Ectopic Pregnancy

1. Lipscomb GH, et al, Predicators of success of MTX treatment in women with tubal ectopic pregnancy. *N Engl J Med*, 1999; 341:1974-8.
2. ACOG Practice Bulletin, Number 3, 1998.
3. Kadar N, Caldwell BV, et al, A method of screening for ectopic pregnancy and its indications. *Obstet Gynecol*, 1981; 58:162-6.
4. Seifer DB, Gutmann JN, Grant WD, Kamp CA, DeCherney AH, Comparison of Persistent Ectopic Pregnancy after Laparoscopic Salpingostomy vs. Salpingostomy at Laparotomy for Ectopic Pregnancy. *Obstet Gynecol*, 1993; 378-382.
5. Wiser-Estin M, DeCherney AH, Diamond MP, Perils in the Differentiation of a Viable Intra-uterine Pregnancy (IUP) from an Ectopic Eccyesis. *Gynecologic Endoscopy*, 1993; 223-226.
6. DeCherney AH, Hade J. Ectopic Pregnancy & Spontaneous Abortion. *Gynecology in Primary Care A Step-by-Step Approach* Scientific American Inc., 1999; 39-45.
7. Pisarska MD, Carson SA. Ectopic Pregnancy. *Danforth's OB & GYN* – Eds: Scott D, Hammond S, Spellacy. 2000 in press.
8. Pisarska MD, Carson SA, and Bustave. Ectopic Pregnancy. *Lancet* 1998; Vol 351:1115-20.

9. Graczykowski JN, and Seifer. Diagnosis of Acute & Persistent Ectopic Pregnancy. *Clinical Ob/Gyn* 1999; 9-22.
10. Buster JE, Pisarska MD. Medical Management of Ectopic Pregnancy. *Clinical OB & GYN*. 1999; 23-30.
11. Tulandi T. *Atlas of Laparoscopic Techniques for the Gynecologist*. Saunders 1994.

Endocrinology of Pregnancy

1. Tulchinsky, Little. *Maternal-Fetal Endocrinology*. 1994 (Saunders)
2. C. Richard Parker, Jr. The Endocrinology of Pregnancy. *Textbook of Reproductive Medicine*, 2nd ed. 1998 (Appleton & Lange) 19-45.
3. Carr BR. The Maternal-Fetal-Placental Unit. Principles and Practice of Endocrinology and Metabolism, 2nd ed. 1995. (JB Lippincott Company) 987-1000.
4. Caspo AI. Effects of Luteectomy and progesterone replacement in early pregnant patients. *American Journal of Obstet & Gynecol* 1973; vol 115:759.
5. Liu, JH Rebar RW. *Endocrinology of Pregnancy. Maternal Fetal Medicine*. Creasy-Resnik Publishing WB Saunders, 4th edition. 1999; pgs. 379-392.
6. Casey ML, Winkel CA, Porter JC, MacDonald PC. Endocrine Regulation of the initiation and maintenance of parturition. *Clinical Perinatol*. 1983 Oct; 10(3): 709-21.
7. Challis JR, Matthews SG, Van Meir, C, Ramirez MM. Current topic: The Placental corticotrophin-releasing hormone-adrenocorticotrophin axis. *Placenta*. 1995 Sept; 16(6): 481-502.

Endometriosis

1. Sampson JA. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. *Am J Obstet Gynecol* 1927; Vol 71:422-69.
2. Dizerga GS, Barber DL, Hodgen GD. Endometriosis the role of ovarian steroids in initiation: Maintenance and suppression. *Fertil Steril* 1980 Vol 33: 649-53.
3. Halme J, Becker S, Haskell S. Altered maturation and function of peritoneal macrophages possible role of pathogenesis of endometriosis. *Am J Obstet Gynecol* 1987; Vol 56: 783-789.
4. Macoux S, Maheux R, Berube S, et al. Canadian Collaboration Group on Endometriosis. Laparoscopic surgery in infertile women with minimal or mild endometriosis. *N Eng J Med* 1997; Vol 337:212-22.
5. Hornstein, MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add Back Study Group. *Obstet Gynecol* 1998; Jan 91(11):16-24.

Hirsutism/androgen excess

1. Ferriman D, Gallwey JD. Clinical Assessment of Body Hair Growth in Women. *J Clin Endocrinol Metab.* 1961; 21:1440-1447.
2. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does Ethnicity influence the prevalence of Adrenal Androgynism in PCOS? *Am J Obstet Gynecol* 1992; 167:1807-12.
3. Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome: Mechanisms & implication for pathogenesis. *Endocrine Reviews* 1997; 18: 777-800.
4. Knochenhauer ES, Key TJ, Kahr-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the Polycystic Ovarian Syndrome in Unselected Black & White Women of the Southeastern United States. *J Clin Endocrinol* 1998; 83: 3078-3082.
5. Yen SSC, Bela P, Rankin J. Inappropriate Secretion of Follicle-Stimulating Hormone & Luteinizing Hormone in Polycystic Ovarian Syndrome. *J Clin Endocrinol Metab.* 1975; 30:435.
6. Rittmaster RS, Hirsutism. *Lancet* 1997; Jan 18:349(9046) 191-5
7. Moghetti P, Tosi F, Tosi A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo M, Castello R. Comparison of Spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism; a randomized, double blind, placebo-controlled trial. *J Clin Endocrinol Metab.* 2000. Jan 85(1): 89-94.
8. Venturolo S, Marescalchi O, Colombo FM, Macrelli S, Ravaioli B, Bagnoli A, Paradisi R, Flamigni C. A prospective randomized trial comparing low-dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. *J Clin Endocrinol Metab* 1999; Apr 84(4): 1304-10.
9. Serafini P, Lobo RA. Increased 5 alpha-reductase activity in idiopathic hirsutism. *Fertil and Steril* 1985 Jan; 43(1): 74-8

Hormonal Contraception

1. Carr BR. Fertility Control and its complications. *Williams Textbook of Endocrinology*, 9th ed. 1998; (WB Saunders) 901-925.
2. Speroff L, Darney. A Clinical Guide for Contraception. (Williams & Wilkins) 1996.
3. Hatcher, RA et al. Contraceptive Technology, 17th ed. Ardent Media 1998.
4. Speroff L, Darney P. A Clinical Guide for Contraception. Wilkins & Wilkins 2000; pg 450.
5. Asbell B. The Pill: A Biography of the drug that changed the world. Random House 1995; 411 pp
6. Vessey MP, Villard-Mackintosh I, McPherson K, Yeates D. Mortality among oral contraceptive users: 20 year follow up of women in a cohort study. *Br Med J* 1989; 299:1487.

7. Collaborative Group on Hormonal Factors in Breast Cancer. Breast Cancer and hormonal contraceptives: collaborative analysis of individual data of 53,297 women with and 100,239 without breast cancer. *Lancet* 1996; 347:1713-27.
8. Fauser IS, Tiitinen A, Affandi B et al. Statement and background review. *Contraception* 1998; 57:1.
9. Mishell DR, Jr. Noncontraceptive Health Benefits of Oral Steriodial Contraceptives. *Am J Obstet & Gynecol.* 1982; 142:809.
10. Dorflinger L. Relative Potency of Progestins used in Oral Contraceptives. *Contraception*. 1985; 557:31.
11. Meade TW. Oral Contraceptives, Clotting factors & Thrombosis. *Am J Obstet Gynecol.* 1982; 142:758.
12. Clarkson TB, Shively CA, Morgan TM, Koritnik DR, Adams MR, Kaplan JR. Oral Contraceptives and Coronary Artery Atherosclerosis of Cynomolgus Monkeys. *Obstet & Gynecology*. 1990; Feb 75(2) 217-2.
13. Schlesselman JJ. Net efforts of oral contraceptive use on the risk of cancer in women in the US. *Obstet & Gynecol.* 1995; 85:793.
14. Adams MR, Clarkson TB, Kortnik DR et al. Contraceptive Steroids & Coronary Artery Atherosclerosis in Cynomolgus Macaques. *Fertil Steril* 1990; 75: 217.

Infertility: Advanced Sperm Testing

1. Burkman LJ, Coddington CC, Franken D, et al. The hemizona assay (HZA): development of a diagnostic test for the binding of human spermatoza to the human hemizona pellucida to predict fertilization potential. *Fertil Steril* 1988; 688-697.
2. Coddington CC, Ochninger SC, Olive DL, et al. Hemizona indez (HZI) demonstrated excellent predictability when evaluating sperm fertilizing capacity in in-vitro fertilization patients. *J Androl* 1994; pgs 250-254.
3. Liu DY, Baker HWG. Tests of human sperm function and fertilization in vitro. *Fertil Steril* 1992; 465-483.
4. Ochninger S, Coddington CC, Scott R et al. Hemizona Assay: assessment of sperm dysfunction and prediction of in vitro fertilization outcome. *Fertil Steril* 1989; 665-670.
5. Yanagimachi R, Yanagimachi H, Rogers BJ. The use of zona-free annual oval as a test system for the assessment of the fertilizing capacity of human sperm. *Biol Reprod* 1976; 471-476.

Infertility: ART

1. Hughes EG, Fedorkou DM, Daya S. et al. The routine use of gonadotropin – releasing hormone agonist. . . . *Fertil Steril* 1992; 58:888.
2. Toner JP, Philput CB, Jones GS, et al. Basal follicle-stimulating hormone level . . *Fertil Steril* 1991; 55:784.

3. Mansour R, Aboulghar M, Serour G. Dummy embryo transfer: a technique *Fertil Steril* 1990; 54:678.
4. Van Steirteghem AC, Liu J, Jones H et al. High Fertilization and implantation rates after. . . . *Human Reprod.* 1993; 8:1061.
5. Cohen J, Alikani M, Trowbridge J et al. Implantation enhancement by selective assisted hatching. *Human Reprod.* 1992; 7:685.
6. Gardner DK, Schoolcraft WB, Wagley L et al. A prospective randomized trial of blastocyst culture and transfer in in-vitro fertilization. *Human Reprod* 1998; 13:34-40.

Infertility: hMG

1. Franks S. Ovulation Induction: Gonadotropins. *Reproductive Endocrinology, Surgery and Technology.* 1996; 1207-1225.
2. Filicori M, Flamigni C. Consensus Session on Ovulation Induction. Treatment of Infertility: *The New Frontiers.* 1998; 125-164.
3. Barbieri RL, (in Yen, Jaffe, Barbieri) Infertility (Chapt 20) and Assisted Reproduction (Chapt 21) *Reproductive Endocrinology*, 4th ed. 1999; 563-621.
4. Homburg R, Howles CM. Low-dose FSH Therapy for anovulatory infertility PCOS. *Human Reprod Update.* 1999; (Sept-Oct 15) 493-499.
5. Filicori M, Flamigni-editors, Baird DTA, Howles CM. Ovulation Induction with gonadotropins. *Ovulation Induction – Basic Science and Clinical Advances.* 1994; 125-176.
6. Insler V, Lunenfeld B. Human Gonadotropins. *Infertility – Male and Female.* 1993; 387-417.
7. Blumenfeld Z. Ovulation Induction: Traditional Superovulation with Gonadotropins. *Manual of Ovulation Induction* (ed: Deepak Shah) IN PRESS 2000 ??????
8. Hull MR, Gonadotropin Therapy in anovulatory infertility. *Gonadotropins GnRH-a, and Growth Factors in Infertility.* 1991; 56-70.
9. Shoham Z, Howles CM, Jacobs HS. *Female Infertility, Therapy, Current Practice.* 1999; Section IV.
10. Homburg R, Levy T. A comparative study of conventional regimen with low-dose FSH *Fertil Steril* 1995; 729-733.

Infertility: Male factor

1. Howards SS. Current Concepts: Treatment of Male Infertility. *New Engl Jnl Med.* 1955; Vol 332:312-317.
2. Pryor JL, Kent-First M, MuallenA, Van Bergen AH, Nolten WE, Meisner I, Roberts KP. Microdeletions in the Y Chromosome of Infertile Men. *New Eng Jnl Med.* 1997; Vol 336(8): 534-9.
3. Madgar I, et al. Controlled trial of High Spermatic Vein Ligation for Varicocele in Infertile Men. *Fertil Steril.* 1995; Vol 63: 120.

4. Mulhall JP, Burgess CM, Cunningham D, Carson R, Harris D, Oates RD. Presence of Mature Sperm in Testicular Parenchyma of Men with Nonobstructive Azoospermia: Prevalance and Predictive Factors. *Urology*; 1997; Vol 49 (1): 91-5; discussion 95-6.
5. Kruger TF, Acosta AA, Simmons KF, Swanson RJ, Matta JF, Veeck LL, Morshedi M, Brugo S. New Method of Evaluating Sperm Morphology with Predictive Value for Human In Vitro Fertilization. *Urology*. 1987; Vol 30 (3): 248-51.

Infertility: Ovulatory Factor

1. Greenblatt RB, Barfield WE, Juneck EC, Ray FW. Induction of Ovulation with MRL-41. *JAMA* 1961; 178:101-106.
2. Kerin JF, Liu JH, Phillipou G., Yen SSC, Evidence for a Hypothalamic Site of Action of CC in Women. *JCEM* 1985; 61: 265-268.
3. Zhuang L, Adashi EY, Hsueh AJ. Direct Enhancement of Gonadotropin-Stimulated Estrogen Biosynthesis by Estrogen & CL. *Endocrinology* 1982; 110: 2219-2225.
4. Wu CH, Winkel CA. The Effect of Therapy initiation Day on CC Therapy. *Fertil Steril* 1989; 52: 564-568.
5. Daly DC, Walters CA, Soto-Albors, CE et al. A randomized study of Dexamethasone in ovulation induction with CC. 1984; 41: 844-848.
6. Tietze C,. Reproductive span and rate of reproduction among Hutterite women. *Fertil Steril* 1957; 89
7. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. *American Journal Obstetrics and Gynecology*. 1935 pg 181
8. Kettle LM, Roseff SJ, Berga SL, Mortola JF, Yen SS. Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. *Fertil Steril* 1993 pg. 532-8.
9. Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. *Human Reproduction*. 1995 pgs. 2705-12.
10. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induces ovulation in the polycystic ovary syndrome. *New England Journal of Medicine* 1998; pgs. 1876-80.

Infertility: Surgery

1. Langer R, Raziel A, Ron-El R, et al. Reproductive outcome after conservative surgery for unruptured tubal pregnancy: a 15-year experience. *Fertil Steril*.1990; 53::227.
2. Murphy AA, Schlaff WD, Sassiakos D, et al. Laparoscopic cautery in the treatment of endometriosis-related infertility. *Fertil Steril* 1991; 55: 246

3. Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. *Am J Obstet Gynecol*. 1993; 168:1759.
4. Rock JA, Guzick DS, Katz E, et al. Tubal anastomosis: pregnancy success following reversal of Falope ring or monopolar cautery sterilization. *Fertil Steril*. 1987; 48:13.
5. Schlaff WD, Hassiakos DK, Damewood MD, et al. Neosalpingostomy and distal tubal obstruction: prognostic factors and impact of surgical technique. *Fertil Steril* 1990; 54: 984.
6. Velde ER, Boer ME, Looman CWN, et al. Factors Influencing Success or Failure after Reversal of Sterilization: A multivariate approach. *Fertil & Steril* 1990; 54: 270.
7. Marcoux, S, Maheux R, Berube S. Laparoscopic Surgery in infertile women with minimal or mild endometriosis. *New Engl J Med* 1997; Vol 33(4):217-222.
8. Schlaff WD, Hasiakos DK, Damewood MD, Rock JA. Neosalpingostomy for distal tubal obstruction; prognostic factors & impacts. *Fertil Steril* 1990; 54(6):984-90.
9. Rock JA, Berquist CA, Kimbal AW Jr., et al. Comparison of the operating microscope & loupe for microsurgical tubal anastomosis: a randomized clinical trial. *Fertil Steril* 1984; 41:229.
10. Vermesh M, Silva PD, Rosen CF, Stein AL, Fossum GT. Management of unruptured ectopic gestation by linear salpingostomy: a prospective randomized clinical trial of laparscopy vs laparotomy. *Obstet Gynecol* 1989; 74(2):282-3
11. Pittaway DE. Appendectomy with the surgical treatment of endometriosis. *Obstet Gynecol* 1983; 61(4):421-4.

Infertility: Tubal factor

1. Boer-Meisel ME, te Velde ER, Habbema JDF, Karduan JWPF. Predicting the pregnancy outcome in patients treated for hydrosalpinx: a prospective study. *Fertil Steril* 1986; 45(1):23-29.
2. Mage G, Pouly JL, de Joliniere JB, Chabrand S, Riouallon A, Bruhat M-A. A preoperative classification to predict the intrauterine and ectopic pregnancy rates after distal tubal surgery. *Fertil Steril* 1986; 46(5):807-10.
3. Scudamore IW, Dunphy BC, Bowman M, Jenkins J, Cooke ID. Comparison of ampullary assessment by falloposcopy and salpingoscopy. *Human Reprod* 1994; 9:1516-18.
4. Canis M, Mage G, Pouly JL, Manhes H, Wattiez A, Bruhat MA. Laparoscopic distal tuboplasty: report of 87 cases and a 4-year experience. *Fertil Steril* 1991; 56:616-21.
5. Jansen RPS. Surgery-pregnancy time intervals after salpingolysis, unilateral salpingostomy and bilateral salpingostomy. *Fertil Steril* 1980; 34:222-25.
6. Novy MJ, Thurmond AS. Proximal tubal obstruction. In: Decision making in reproductive endocrinology. Schlaff WD and Rock JA (eds). Blackwell Scientific Publications, Boston MA. Pp 477-487, 1993.
7. Gomel V. Tubal reanastomosis by microsurgery. *Fertil Steril* 1977; 28:59-65.

Infertility: Unexplained

1. Berube S, Marcoux S, Langevin M, Maheux R, The Canadian Collaborative Group on Endometriosis. Fecundity of infertile women with minimal or mild endometriosis and women with unexplained infertility. *Fertil Steril* 1998; 69:1034-1041.
2. Donderwinkel PF, van der Vaart H, Wolters VM, Simons AH, Kroon G, Heineman MJ. Treatment of patients with longstanding unexplained subfertility with in vitro fertilization. *Fertil Steril* 2000; 73:334-337.
3. Guzick DS, Sullivan MW, Adamson GD, Cedars MI, Falk RJ, Peterson EP et al. Efficacy of treatment for unexplained infertility. *Fertil Steril* 1998; 70:207-213.
4. Martin JS, Nisker JA, Parker JI, Kaplan B, Tummon IS, Yuzpe AA. The pregnancy rates of cohorts of idiopathic infertility couples gives insights into the underlying mechanism of infertility. *Fertil Steril* 1995; 64:98-102.
5. Silverberg KM. Ovulation induction in the ovulatory woman. *Sem Reprod Endocrinol* 1996; 14:339-44.

Menopause (General)

1. Avis NE, McKinlay SM. A longitudinal analysis of women's attitudes toward the menopause: results from the Massachusetts Women's Health Study. *Maturitas* 1991; 13:65-79.
2. McNaughton J, Banah M, McCloud P, Hee J, Burger H. Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. *Clin Endocrinol* 1992; 36:339.
3. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. *J. Clin Endocrinol Metab* 1996; 81: 1495-01.
4. Meldrum DR, Davidson BJ, Tataryn IV, Judd HL. Changes in circulating steroids with aging in postmenopausal women. *Obstet Gynecol* 1981; 57: 624.
5. Grodin JM, Siiteri PK, McDonald PC. Source of estrogen production in postmenopausal women. *J. Clin Endocrinol Metab* 1963; 36:207.
6. Longcope C, Jaffe W, Griffing G. Production rates of androgens and oestrogens in post-menopausal women. *Maturitas* 1981; 3:215.
7. Semmens JP, Wagner G, Effects of estrogen therapy on vaginal physiology during menopause. *Obstet Gynecol* 1985; 66: 15-18.
8. Schiff I, Regestein Q, Tulchinsky D, Ryan KJ. Effects of estrogens on sleep and psychological state of hypogonadal women. *JAMA* 1979; 242: 2405-07.

Menopause: Alternatives to HRT

1. Taylor, Maida. Alternatives to Conventional Hormone Replacement. *Menopausal Medicine.* (ASRM) Vol 6 #3 1998 1-6.
2. Santen R, Pinkerton J. Alternatives to Estrogen Use in Post-menopausal Women. *Menopausal Medicine.* (ASRM) Vol 7 #4 1999; 1-7.
3. North American Menopause Society and expert panel. NAMS consensus Opinion on Isoflavones. Menopause (**scheduled to appear in June/July 2000 issue of journal).
4. Hale G, Bievre M, Hughes C. Exploring the role of Progestins and Phytoestrogens in Menopause. *Integrative Medicine* (**scheduled to appear in journal).
5. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. *JAMA* 1998; Volume 280, pg 1569-75.
6. Seidl MM, Stewart DE. Alternative treatments for menopausal symptoms. Systematic review of scientific and lay literature. *Can Family Physician* 1998; Vol 44, pg 1299-308.
7. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. *Fert Steril* 1997; Vol 68, pgs 981-6.
8. Wagner JD, Cefalu WT, Anthony MS, Litwak KN, Zhang L, Clarkson TB. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesterol ester content in ovariectomized cynomolgus monkeys. *Metabolism* 1997; Vol 46, pg 698-705.
9. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. *Am J Obstet Gynecol* 1992; Vol 167, pg 436-9.

Menopause: Breast cancer

1. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. *New Engl J Med* 1995; 332: 1589.
2. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk of breast cancer and total mortality in women with a family history of breast cancer. *Ann Intern Med* 1997; 127: 973-80.
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast Cancer and epidemiological studies of 52,706 women with breast cancer and 108,411 women without breast cancer. *Lancet* 1997; 350: 1047-59.
4. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. *Obstet and Gynecol* 1995; 85:1.
5. Foidart J-M, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. *Fertil Steril* 1998; 69: 963-69.

6. Grodstein F, Stampfer M, Colditz G, Willett W, Manson J, Joffe M, Rosner B, Fuchs C, Hankinson S, Hunter D, Hennekens C, Speizer F. Postmenopausal Hormone Therapy & Mortality. *New Eng J Med.* 1997; 336(17):1769-1775
7. Jordan C, Morrow M. Tamoxifen, Raloxifene and the Prevention of Breast Cancer. *Endocrine Reviews.* 1999; 20(2):253-278.
8. Fowble B, Goodman R, Glick J, Rosato E. Breast Cancer Treatment: A Comprehensive Guide to Management. 1991
9. Hammond CB. Menopause and HRT: An Overview. *Obstetrics and Gynecology* 1996; 87(2):333-340.
10. Lobo RA, Speroff L. International Consensus Conference on Postmenopausal Hormone Therapy and Cardiovascular System. *Fertil Steril* 1994; 62(Suppl 2):1763-1795.
11. Gambrell RD. Prevention of Endometrial Cancer with Progesterone. *Maturitas* 1986; 8:159-168.
12. Andrews WC. The Transitional Years and Beyond. *Obstet and Gynecologists.* 1995; 85: 1-5.

Menopause: Cardiovascular Disease

1. Downs JR, Clearfield M, Wies S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study [see comments]. *JAMA*, 1998; 279: 1615-22.
2. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group [see comments]. *JAMA* 1998; 280: 605-13.
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of Cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344(8928):1383-89.
4. Rossouw JE. Estrogens for prevention of coronary heart disease. Putting the brakes on the bandwagon [see comments]. Review [36 refs] *Circulation* 1996; 94: 2982-85.
5. Roussouw JE, Hurd S. The Women's Health Initiative: recruitment complete—looking back and looking forward [editorial]. *Journal of Women's Health* 1999; 8:3-5.
6. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease [see comments] [published erratum appears in the N Eng J Med 1996 Oct 31; 335 (18): 1406. *New England J Medicine* 1996; 335: 453-61].
7. Manson JE. Walking as effective as Vigorous Exercise at Preventing CHD in Women. *N Eng J Med* 1999; 341: 650-58.
8. Wren BG. Megatrials of hormonal replacement therapy. [Review] [24 refs]. *Drugs & Aging.* 1998; 12: 343-48.

Menopause: Osteoporosis

1. Genant HK, Engelke K, Fuerst T, Gluer C, Grampp S, Harris ST, Jergas M, Lang T, Lu Y, Majumdar S, Mathur A, Takada M. BONE DENSITY, DEXA, OSTEOPOROSIS, REVIEW, TECHNIQUE: ULTRASOUND. Noninvasive assessment of bone mineral and structure: state of the art. *Journal of Bone and Mineral Research*. 1996; 11:707-730.
2. Hanley DA, Josse RG. OSTEOPOROSIS: REVIEW. Prevention and management of osteoporosis: consensus statements from the scientific advisory board of the Osteoporosis Society of Canada. *Canadian Med Assoc Journal* 1996; 155: 921-929.
3. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. CALCIUM, FRACTURE, OSTEOPOROSIS, VITAMIN D, WOMEN. Vitamin D3 and calcium to prevent hip fractures in elderly women. *N Engl. J Med.* 1992; 327: 1637-1642.
4. Beardsworth SA, Kearney CE, Purdie DW. BONE, OSTEOPOROSIS, PREVENTION, TIBOLONE. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomized controlled trial. *Br. J Obstet. Gynaecol.* 1999; 106(7): 678-683.
5. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA. ALENDRONATE: HRT , OSTEOPOROSIS TREATMENT. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized controlled clinical trial. *J. Clin Endocrinol. Metab.* 1999 84(9) 3076-3081.
6. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Kreuger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. OSTEOPOROSIS: RALOXIFENE. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) Investigators (see comments). *JAMA*. 1999; 282(7): 637-245.
7. Riggs BL, Melton LJ, Eds. Osteoporosis: Etiology, Diagnosis and Management. Phil PA, Lippincott-Raven 1995.
8. National Osteoporosis Foundation. Physicians Guide to Prevention and Treatment of Osteoporosis. *Excerpta Medica* 1998.
9. World Health Organization. Assessment of Fracture Risk and its application to screening for postmenopausal osteoporosis report of a Who study group (Report #848). Geneva, Switz. 1994.
10. Dawson-Hughes B, Weaney RP Eds. Nutritional Aspects of Osteoporosis. NY, NY, Springer. 1998.

Menopause: Normal Transition

1. McKinlay SM, Brambella DJ, Posner NG. The Normal Menopausal Transition. *Maturitas* #14: 1992; pg 102.
2. McKinlay SM, The Normal Menopausal Transition: An Overview. *Maturitas*, 1996: March 23: (2) 137-45.
3. Sherman BW, West JH, Krenman SG. The Menopausal Transition: Analysis of LH, FSH estradiol and Progesterone Concentrations During Menstrual Cycles of Older Women. *JCEM* #42, 1976: pg 29.
4. Mishell D, Jr..Use of Oral Contraceptives in women of Older Reproductive Age. *Am J Obstet & Gynecol.*, #158; 1988: 1652-7.
5. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW. Menopause and Risk Factors for Coronary Heart Disease. *New Eng Jnl of Med*, 1989; Sept 7; 321(10) 641-6.
6. Burger HG, Dudley EC, Hopper JL, Groome N, Gutherie JR, Green A. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the menopausal transition in a population-based cohort of women. *J Clin Endocrinol Metab* 1999, Nov 84(11):4025-4030.

Menopause: Premature ovarian failure

1. Liewan H, Santoro N. Premature Ovarian Failure: A Modern Approach to Diagnosis & Treatment. *The Endocrinologist* 1997; Vol 7:314-321.
2. Anasti J. Premature Ovarian Failure: An Update. *Fertil Steril* 1998; Vol 70: 1-15
3. Taylor AL, Adams JM, Molder C, Martin KA, Sluss PM, Crowley WF. A randomized controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea. *JCLM* 1996; Vol 81: 3615-3621.
4. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. *Fertil Steril* 1992; Vol 57: 50-55.
5. McKinlay SM, The Normal Menopausal Transition: An Overview. *Maturitas*, 1996: March 23: (2) 137-45.
6. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW. Menopause and Risk Factors for Coronary Heart Disease. *New Eng Jnl of Med*, 1989; Sept 7; 321(10) 641-6.

Menstrual cycle

1. Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. *Hum Reprod* 1986;1:81-87.
2. McNatty KP, Makris A, Reinhold VN, DeGrazia C, Osathanondh R, Ryan KJ. Metabolism of androstenedione by human ovarian tissues in vitro with particular reference to reductase and aromatase activity. *Steroids* 1979; 34:429.
3. McNatty KP, Smith DM, Makris A, Osathanondh R, Ryan KJ. The microenvironment of the human antral follicle; inter-relationships among the

- steroid levels in antral fluid, the population of granulosa cells, and the status of the oocyte in vivo and in vitro. *J Clin Endocrinol Metab* 1979; 49:851.
4. Erickson GF, Magoffin DA, Dyer CA, Hefeditz C. The ovarian androgen producing cells: a review of structure/function relationships. *Endocr Rev* 1985; 6:371.
 5. Goodman AL, Hodgen GD. The ovarian triad of the primate menstrual cycle. *Recent Prog Hor Res* 1983; 39:1-73.
 6. Young JR, Jaffe RB. Strength-duration characteristics of estrogen effects on gonadotropin response to gonadotropin-releasing hormone in women. II. Effects of varying concentrations of estradiol. *J Clin Endocrinol Metab* 1976; 42:432.
 7. Filicori M, Santoro N, Merriam GR, Crowley Jr WF. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. *J. Clin Endocrinol Metab* 1986; 62:1136.
 8. Nakai Y, Plant TM, Hess DL, Keogh EJ, Knobil E. On the sites of the negative and positive feedback actions of estradiol in the control of gonadotropin secretion in the rhesus monkey. *Endocrinology* 1978;102:1008.
 9. Knobil E. The neuroendocrine control of the menstrual cycle. *Recent Prog Horm Res* 1980; 36:53.
 10. Groome NP, Illingworth PG, O'Brien M, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. *J. Clin Endocrinol Metab* 1996; 81: 1401-05.
 11. El-Roeiy A, Chen X, Roberts VJ, LeRoith D, Roberts Jr, CT, Yen SSC. Expression of insulin-like growth factor-I (IGF-I) and IGF-II and the IGF-I, IGF-II, and insulin receptor genes and localization of the gene products in the human ovary. *J Clin Endocrinol Metab* 1993; 77:1411.
 12. Adashi EY, Resnick CE, Hurwitz A, Riciarelli E, Hernandez ER, Rosenfeld RG. Ovarian granulosa cell-derived insulin-like growth factor binding proteins; modulatory role of follicle-stimulating hormone. *Endocrinology* 1991; 128-754.
 13. Liu JH, Yen SSC. Induction of midcycle gonadotropin surge by ovarian steroids in women; a critical evaluation. *J. Clin Endocrinol Metab* 1983; 57:797.
 14. Yoshimura Y, Wallach EE. Studies on the mechanism(s) of mammalian ovulation. *Fertil Steril* 1987; 47:22.
 15. Treloar AE, Boynton RE, Borghild GB, Brown BW. Variation of the human menstrual cycle through reproductive life. *Int J Fertil* 1967; 12:77-126.

Premenstrual Syndrome

1. Muse KN, Cetel NS, Futterman LA, Yen SSC. The premenstrual syndrome: Effects of “medical oophorectomy”. *N Engl J Med* 1984; 311:1345-9.
2. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. *NEJM* 1998; 3348(4):209-16.
3. Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. *Am J Obstet Gynecol* 1990; 162(1): 105-9.

4. Steiner M, Steinberg G, Stewart D, Carter D, Berger C, Reid R, Grover D, Streiner D. Fluoxetine in the treatment of premenstrual dyshoria. *NEJM* 1995; 332: 1529-34.
5. Mortola JF, Girton L, Beck L, et al. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument. The calendar of premenstrual experiences. *Obstet Gynecol* 1990; 76:302-6.
6. Reid, RL, Yen SSC. The Premenstrual Syndrome. *Am J Obstet Gynecol* 1981; 139:85-104.
7. Casson P, Hahn PM, Van Vogt DA, Reid RL. Lasting Response to Ovariectomy in Severe Intractable Premenstrual Syndrome. *Am J Obstet Gynecol* 1990; 162-199.
8. Mortola JF, Girton L, Fischer U. Successful Treatment of Severe Premenstrual Syndrome by Combined Use of Gonadotropin-releasing Hormone Agonist and Estrogen/Progestin. *J. Clin Endocrinol Metab* 1991; 72:252A-252F.
9. Steiner M, Korzekwa M, Lamont J, Stewart D, Carter D, Misri S, Reid RL, Steinberg, S, Berger C, Grover D. Fluoxetine in the Treatment of Premenstrual Dysphoria. *New Engl J Med* 1995; 332(23): 1529-1534.
10. Woods NF, Most A, Dery GK. Prevalence of Perimenstrual Symptoms. *Am J Public Health* 1982; 72:1257.
11. Endicott J, Nee J, Cohen J, Halbreich U. Premenstrual Changes: Patterns and Correlates of Daily Ratings. *J Affect Disord* 1986 March-April; 10(2): 127-35.
12. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. *Arch Gen Psychiatry* 1999; Oct 56(10): 932-9.
13. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T, Severino S, Stout A, Stone A, Harrison, W. Symptomatic improvement of Premenstrual Dysphoric Disorder with Sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. *JAMA* 1997; Sept 24, 278(12):983-8.

Prolactin Disorders

1. Hwang P, Guyda H, Friesen H. A radioimmunoassay for human prolactin Proc. *Natl Acad. Sci. USA* 1971; 68:1902-1906.
2. Tyson JE, Hwang P, Guyda H, et al. Studies of prolactin secretion in human pregnancy. *Am J Obstet Gynecol* 1972; 113:14.
3. Kleinberg DL, Noel GL, Franz AL. Glactorrhea: A Study of 235 cases, including 48 with pituitary tumors. *N Eng J Med* 1997; 296:589.
4. Klibanski A, Neer R, Beitins IZ et al. Decreased bone density in hyperprolactinemic women. *N Eng J Med* 1980; 303:1511.
5. Brenner SH, Lessing JB, Quagliarello J, Weiss G. Hyperprolactinemia and associated pituitary prolactinomas. *Obstet Gynecol* 1985; 65:661-664.
6. Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. *Fertil Steril* 1987; 48:67-71.

Puberty: Ambiguous Genitalia

1. Jost A. Sur le role des gonades foetales dans la differenciation sexuelle somatique de l'embryon de Lapin. *CR Assoc Anat.* 1947; 51: 244.
2. Jost A. Problems of fetal endocrinology: the gonadal and hypophyseal hormones. *Recent Prog Horm Res.* 1953; 8:379-418.
3. Josso N. Anti-mullerian hormone: new perspectives for a sexist molecule. *Endocrine Rev.* 1986; 7:421-433.
4. Wilson JD, Griffin JE, George FW, et al. The role of gonadal steroids in sexual differentiation. *Recent Prog Horm Res.* 1981; 37: 1-39.

Puberty: Congenital reproductive tract abnormalities

1. Jones, Jr, HW, Jones GE. Double Uterus as an etiological factor in repeated abortion: Indications for Surgical Repair. *Am J Obstet & Gynecol.* 1953; 65: 325.
2. McIndoe AH, Banister JB. An Operation for the cure of congenital absence of the vagina. *J Obstet & Gynaecol Br Emp.* 1938; 45: 490.
3. Rock JA, Schlaff WD, Zaccur HA, Jones Jr., HW. The clinical management of congenital absence of the uterine cervix. *Int J Gynaecol Obstet.* 1984; 22: 231-235.
4. Woolf RB, Allen WM. The Frequent, simultaneous occurrence of malformations of the reproductive and urinary tracts. *Obstetrics and Gynecology.* 1953; 2(3): 236-266.

Puberty: Delayed puberty

1. Rosenfeld RL. Diagnosis and Management of Delayed Puberty. *J Clin Endocrinol Metab.* 1990; 559-562.
2. Crowne EC, Shalet SM, Wallace WH, Eminson DM, Price DA. Final heights in girls with untreated constitutional delay in growth and puberty. *Eur J Pediatrics.* 1991; 708-712.
3. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary Sexual Characteristics & menses in young girls seen in office practice; a study from the PROS network. *Pediatrics* 1997; 505-512.
4. Argente J. Diagnosis of Late Puberty. *Horm Res* 1999; Suppl 53: 95-100.
5. Reindollar RH, Byrd JR, McDonough PG, Delayed sexual development: a study of 252 patients. *Am J Obstet Gynecol* 1981; 140:371-80.

Puberty: Precocious development

1. Pescovitz OH, Comite F, Hench K, Barnes K, McNemar A, Foster C, Kenigsberg D, Loriaux DL, Cutler GB Jr., The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing analogue therapy. *J. Pediatric.* 1986; 108:47-54.
2. Feuillann P, Merke D, Leschek EW, Cutler GB Jr. Use of aromatase inhibitors in precocious puberty. *Endocr Relat Cancer.* 1999; 6:303-6.
3. Layman LC, Mutations in human gonadotropin genes and their physiologic significance in pubert and reproduction. *Fertil Steril* 1999; 71:201-18.
4. Malasanos TH, Sexual Development of the fetus and pubertal child. *Clin Obstet Gynecol.* 1997; 40:153-67.
5. DiMeglio LA, Pescovitz OH, Disorders of puberty: inactivating and activating molecular mutations. *J Pediatr* 1997; 131:S8-12.

Recurrent Pregnancy Loss

1. Kutteh WH. Recurrent Pregnancy Loss: Textbook of Reproductive Medicine. Second edition. 1998; 34:679-692.
2. Stephenson MD Frequency of factors associated with habitual abortion in 197 couples. *Fertil Steril* 1996; 66:24-29.
3. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin in superior to low-dose aspirin alone. *Am. J Obstet Gynecol* 1996; 174:1584-1589.
4. Kutteh WH, Stovall DW, Scott JR. The immunologic diagnosis and treatment of recurrent pregnancy loss. Infertility and Reproductive Medicine Clinics of North America. 1997; 8:267-287.
5. Hill JA. Recurrent Pregnancy Loss. *Maternal Fetal Medicine*; Creary and Resnick, 1994; 423-443.
6. Hill JA, Recurrent Pregnancy Loss. *Maternal Fetal Medicine* 4th Ed. 1998.
7. Ober C, Harrison T, Odem RR, Barnes RB, Branch DW, Stephenson MD, Barns B, Wilker MA, Scott JR, Schreiber JR. Mononuclear cell immuniztion as prevention of recurrent miscarriages: A randomized Trial. *Lancet* 1999; pgs 364, 365, 369.
8. Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigating of recurrent miscarriage: Preliminary experience of 500 consecutive cases. *Human Reproduction.* 1994; 9:1328-1332.
9. Warburton D, Kline J, Stein Z, Strobino B. Cytogenetic abnormalities in spontaneous abortion of recognized conceptions. *Prenatal Genetics.* 1986; 23-40.
10. Stray-Pederson B, Stray-Pederson S. Etiologic, crd subsequent reproductive performance in 195 couples with a prior history of habitual abortion. *Am J Obstet & Gynecol* 1984; 148:140-146.